322 11th Avenue SW
Calgary, AB T2R 0C5
Full Time Employees: 29
|Dr. Matthew C. Coffey M.B.A., Ph.D.||Pres, CEO & Director||1.05M||N/A||N/A|
|Mr. Kirk J. Look C.A., CA||Chief Financial Officer||740.85k||N/A||N/A|
|Mr. Andrew R. de Guttadauro||Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc||634.74k||N/A||1967|
|Dr. Thomas C. Heineman M.D., Ph.D.||Chief Medical Officer||872.68k||N/A||N/A|
|Ms. Allison Hagerman P.Eng., P.M.P.||VP of Product Devel.||582.15k||N/A||N/A|
|Jon Patton||Director of Investor Relations & Communication||N/A||N/A||N/A|
|Mr. John Mark Lievonen F.C.A., FCA||Consultant||N/A||N/A||N/A|
|Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D.||Consultant||N/A||N/A||1948|
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.’s ISS Governance QualityScore as of March 1, 2023 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 3; Compensation: 8.